SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

ATRA

Atara Biotherapeutics, Inc.
NASDAQHealth Care

Latest close: 9.18 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 4, 2026Reported purchase · Form 4Brian N Cherry · $1.0MOpen the filing ↗
  2. Aug 26, 2026Notice of sale · Form 144Nguyen AnhCo · Director, Officer · $42.3KOpen the filing ↗
  3. Aug 17, 2026Reported sale · Form 4AnhCo Nguyen, President and CEO · $40.9KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record1,06421 flagged findings
Reported transactions (Form 4)70since Mar 1, 2023 · and 38 other holdings
Corporate events (8-K)30since May 8, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

What the company does

clinical-stage biotechnology company

Source: Wikidata (CC0 1.0) · copied on Sep 3, 2026 · may not reflect recent changes.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “ Staff ”) published Question 116.26…”
  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…stock. There were no shares of preferred stock outstanding as of March 31, 2026 and December 31, 2025. Equity Offerings As part…”
    +1 more passage from the same document
    • “…As of March 31 , 2026, 38,735 and 55,387 of the pre-funded warrants to purchase shares of our common stock issued and sold as part…”
  • 2026-05-12listing compliance noticerecentOpen filing ↗
    “…standards. On April 30, 2026, we received a notice from the Listing Qualifications Department (the Staff) of Nasdaq notifying us that…”
    +1 more passage from the same document
    • “…our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish…”
  • 2026-05-12Department of Justice inquiryrecentOpen filing ↗
    “…product from the market, or require us to initiate a product recall. The occurrence of any event or penalty described above may also…”
  • 2026-05-12reverse splitrecentOpen filing ↗
    “…prevent us from successfully growing our company. Risks Related to Ownership of Our Common Stock Our stock price has been and…”
    +1 more passage from the same document
    • “…tasks could prevent us from successfully growing our company. Risks Related to Ownership of Our Common Stock Our stock price has…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Listing notice in force

The exchange has notified the company that it fails a continued-listing requirement (8-K, item 3.01 of May 1, 2026).

Deadline: Oct 27, 2026

  • market value of listed securities · Nasdaq, rule 5450(b)(2)(A) · notice of Apr 30, 2026 · pending · deadline Oct 27, 2026 (text and rule agree)

Open the 8-K at the SEC

Reverse splits in 5 years

1 reverse split in 5 years (1:25 on Jun 20, 2024) · 1:25 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 1,064)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 4, 26Form 4 ↗Insider transaction
  • Aug 26, 26Form 144 ↗Notice of proposed sale
  • Aug 26, 26Form 4 ↗Insider transaction
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Point72 Asset Management, L.P. · 7.6% · event on Jun 30, 26 · amendment
  • Aug 12, 2610-Q ↗Quarterly report
  • Aug 12, 268-K ↗Current report · Results
  • Jul 24, 26Form 4 ↗Insider transaction
  • Jul 24, 26SCHEDULE 13D/A ↗Stake with intent to influence · Redmile Group, LLC · 9.9% · event on Jul 22, 26 · amendment
  • Jul 6, 26Form 3 ↗Insider transaction
  • Jun 26, 268-K ↗Current report · A senior executive left or was appointed
  • Jun 15, 26Form 4 ↗Insider transaction
  • Jun 15, 26Form 3 ↗Insider transaction
  • Jun 12, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • May 14, 26SCHEDULE 13D/A ↗Stake with intent to influence · Redmile Group, LLC · 9.9% · event on May 12, 26 · amendment
  • May 13, 26SCHEDULE 13G ↗Passive stake · Adage Capital Management, L.P. · 8.6% · event on Mar 31, 26
  • May 12, 26424B5 ↗Securities offering
  • May 12, 2610-Q ↗Quarterly report
  • May 12, 268-K ↗Current report · Financial statements and exhibits

1,064 filings on record, the oldest from Oct 15, 14.

Listing the 25 most recent filings of the 1,064 on record.

8-Ks, explained

Stress9Structure20Governance40
  • Jun 26, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Jun 12, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • May 1, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Feb 23, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Jan 2, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Oct 7, 25StressRestructuring plan with committed costs8-K 2.05 ↗
  • Sep 4, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • May 15, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • May 12, 25StressRestructuring plan with committed costs8-K 2.05 ↗
  • Apr 4, 25StructureEntered a material agreement8-K 1.01 ↗
  • Mar 31, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Mar 3, 25StressRestructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗

14 older filings not shown · The record reaches back to Jan 21, 15.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Jan 27, 25StressRestructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
  • Jan 9, 24StressListing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
  • Jan 8, 24StressRestructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗
  • Nov 1, 23StressRestructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
  • Aug 8, 22StressRestructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗

The full record holds 9 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Adiumentum Capital Fund I LP20.0%May 14, 25SCHEDULE 13D/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Panacea Innovation Limited16.1%May 7, 26SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Redmile Group, LLC9.9%Jul 22, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • EcoR1 Capital, LLC17.4%May 7, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Redmile Group, LLC9.9%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Panacea Venture Healthcare Fund II, L.P.9.5%Jan 30, 25SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Adage Capital Management, L.P.8.6%Mar 31, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Point72 Asset Management, L.P.7.6%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Aug 26, Nguyen AnhCo filed notice of intent to sell up to $42K. That is about 0.05% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

No sale of theirs is on record yet in Form 4; the 90-day window is still open.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 4, 26Buy$1000KBrian N Cherry↗
  • Aug 17, 26Sell$41KAnhCo NguyenPresident and CEO↗
  • May 18, 26Sell$22KYanina Grant-HuertaChief Accounting Officer↗
  • May 18, 26Sell$48KAnhCo NguyenPresident and CEO↗
  • May 7, 26Buy$4.7MEcoR1 Capital, LLC↗
  • May 7, 26Sell$3.2MPanacea Innovation Ltd↗
  • Mar 2, 26Sell$1KAnhCo NguyenPresident and CEO↗
  • Mar 2, 26Sell$295AnhCo NguyenPresident and CEO↗
  • Mar 2, 26Sell$7KAnhCo NguyenPresident and CEO↗
  • Mar 2, 26Sell$7KAnhCo NguyenPresident and CEO↗
  • Mar 2, 26Sell$122Yanina Grant-HuertaChief Accounting Officer↗
  • Mar 2, 26Sell$8KYanina Grant-HuertaChief Accounting Officer↗

There are 16 more transactions in this stretch.

Stock compensation, tax and giftsshow the 12 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jul 22, 26Compensationamount n/aRedmile Group, LLC↗
  • Jul 22, 26Taxamount n/aRedmile Group, LLC↗
  • Jun 11, 26Compensationamount n/aBrian N Cherry↗
  • Jun 9, 26Compensationamount n/aGregory Austin Ciongoli↗
  • Jun 9, 26Compensationamount n/aMatthew K Fust↗
  • Jun 9, 26Compensationamount n/aWILLIAM K HEIDEN↗
  • Mar 17, 26Compensation$26Panacea Innovation Ltd↗
  • Mar 17, 26Tax$26Panacea Innovation Ltd↗
  • Mar 9, 26Compensationamount n/aYanina Grant-HuertaChief Accounting Officer↗
  • Mar 9, 26Compensationamount n/aAnhCo NguyenPresident and CEO↗
  • Nov 28, 25Compensation$5Panacea Innovation Ltd↗
  • Nov 28, 25Tax$14Panacea Innovation Ltd↗

The full record holds 135 transactions and goes back to Feb 7, 23.

Its sector and its market

Atara Biotherapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Atara Biotherapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Atara Biotherapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
1,064 documents on file, from Oct 15, 2014 to Sep 4, 2026.
Company description
Wikidata, read on Sep 3, 2026.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.